Read our Recent Headlines


April 17 Biotech Update

The sector is certainly weak to start the day and obviously this seems driven by the macro. It was not immediately clear to me the trigger for the selling. Was.

Catalyst Watch – Vol. 3, Edition 5 (4/17/15)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

April 15 Biotech Update

It is a busy day so I am going to try and keep this short but every time I write that it seems like I write the same amount if.

Quick Note on GWPH

Embargoed Data was released yesterday in an announcement from AAN regarding GW Pharmaceuticals’ Epidiolex study: https://www.aan.com/PressRoom/Home/PressRelease/1364 This paragraph summarizes the Key Takeaway: “For the 137 people who completed the 12-week.

April 14 Biotech Update

A weak start to the day that essentially appears to be a continuation from the late selling yesterday. It still seems to be the case that large caps are underperforming.

April 13 Biotech Update

Happy merger Monday- well, happy Monday at least. The sector is off to a good start this week despite another dearth of deals this morning. It does worry me a.

April 10 Biotech Update

A good opening to the sector and large caps but the move was almost immediately faded (especially the large caps). Yesterday ended better than the past, so perhaps the sector.

Introduction


Quick Facts

10

Analysts

500

Clients

22k

Followers

900

Reports

2.7k

Comments

5

Years

Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!